Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Cancelled).

Claim 2 (Previously Presented). The method according to claim 27, wherein the donor cells contain naturally occurring stem cells.

Claim 3 (Currently Amended). The method according to claim 27, wherein the step of cultivating further comprises preparing the cells of the morula or the internal cell mass of the blastocyst ~~are prepared~~ in a culture dish or preparing ~~are used to prepare~~ a soluble matrix fraction from the cells, and wherein the step of supplying comprising placing the donor cells to the culture dish or soluble matrix fraction.

Claim 4 (Previously Presented). The method according to claim 27, wherein the donor cells are obtained from umbilical cord blood.

Claim 5 (Withdrawn). The method according to claim 27, wherein the donor cells are obtained from placenta.

Claim 6 (Withdrawn). The method according to claim 27, wherein the donor cells are obtained from bone marrow.

Claim 7 (Withdrawn). The method according to claim 27, wherein the donor cells are obtained from fatty tissue.

Claim 8 (Previously Presented). The method according to claim 27, wherein the cells of the morula or the internal cell mass of the blastocyst are tetraploid cells.

Claim 9 (Previously Presented). The method according to claim 27, wherein the cells of the morula or the internal cell mass of the blastocyst has cells whose genome contains vectors that cause a lethal sensitivity to appropriate cultivation conditions in comparison to the wild type.

Claim 10 (Previously Presented). The method according to claim 27, wherein the genome of the donor cells contains a vector which causes a resistance to additives of culture media.

Claim 11 (Previously Presented). The method according to claim 27, wherein the survivability of the cells of the morula or the internal cell mass of the blastocyst is reduced by adding selected antibodies.

Claim 12 (Previously Presented). The method according to claim 9, wherein the survivability of the cells of the morula or the cells of the internal cell mass of the blastocyst is reduced in a way that is tailored to the varying degrees of differentiation of the donor cells and is chronologically well-ordered.

Claim 13 (Previously Presented). The method according to claim 27, wherein before the donor cells are supplied into the morula or the blastocyst, the donor cells are brought into contact in culture dishes with other blastocysts or internal cell masses isolated from other blastocysts, and those donor cells having a relatively high contact affinity are isolated and supplied to the morula and/or blastocyst first cited.

Claim 14 (Previously Presented). The method according to claim 27, wherein before the donor cells are supplied into the morula or the blastocyst, the donor cells are equipped with a

genetic marker that ensures cells having a lower degree of differentiation are isolated and supplied into the morula or blastocyst.

Claim 15 (Withdrawn). The method according to claim 27, wherein the morula or blastocyst is a mouse morula or mouse blastocyst.

Claim 16 (Previously Presented). The method according to claim 27, wherein the morula or blastocyst is a pig morula or pig blastocyst.

Claim 17 (Previously Presented). The method according to claim 27, wherein when the donor cells are supplied to a blastocyst, the supply is performed through injection.

Claim 18 (Withdrawn). The method according to claim 27, wherein when the donor cells are supplied to a morula, the supply is performed through aggregation.

Claims 19-22 (Cancelled).

Claim 23 (Withdrawn). The method according to claim 27, wherein the donor cells are donor cells of non-human mammals.

Claims 24-26 (Cancelled).

Claim 27 (Currently Amended). A method for producing cell lines or individual organs comprising the steps of:

(a) cultivating a nonhuman morula or a nonhuman blastocyst under conditions that enable a further development of the morula or blastocyst to occur in stages in which newly formed cell lines having a high degree of differentiation are produced;

(b) supplying differentiable <u>human</u> donor cells to the morula or the blastocyst to produce cell lines; and

(c) isolating the cell lines or further differentiating the cell lines into organs through transfer of the blastocyst into a surrogate mother animal;

wherein the cells of the morula or an internal cell mass of the blastocyst have a restricted survivability in comparison to a corresponding wild type or survivability of the cells or the internal cell mass is reduced through selected cultivation conditions; and

wherein the donor cells supplied to the morula or blastocyst have varying degrees of differentiation and are not isolated from an embryo or pre-embryo ~~of non-embryonic origin~~.